Skip to main content

Table 1 Clinical and pathological characteristics of the WGS study cohort

From: Detection of ctDNA in plasma of patients with clinically localised prostate cancer is associated with rapid disease progression

Sample

Age

PSA

Prior RT

cT

Bx GG

Staging

RP GG

pT

Vol (cc)

11193_2

70

26.9

y

cT1c

5

MRI

WBBS

5

pT3b

21.3

11196_3

57

9.3

y

cT1c

3

MRI

WBBS

3

pT3b

2.1

11201_4

64

8.1

n

cT3a

5

CT

WBBS

5

pT3b

18.5

11199_5

67

7.8

n

cT2a

2

MRI

3

pT3a

15.2

11219_6

58

6.5

n

cT1c

2

MRI

2

pT3a

2.1

11231_9

59

6.1

n

cT1c

2

MRI

2

pT2c

3.7

11242_10

61

4.1

n

cT2a

2

CT

WBBS

2

pT3a

3.7

11243_11

76

7.9

n

cT2a

5

CT

WBBS

3

pT3a

7.5

  1. PSA prostate-specific antigen, RT radiotherapy, cT clinical stage, Bx diagnostic biopsy, GG International Society of Urological Pathology Grade Group, RP radical prostatectomy, pT pathological stage, Vol (cc) tumour volume (cm3)